Citat:
Ursprungligen postat av
Pica-pikant
Du har fortfarande inte länkat till någon studie. Kan det vara så enkelt att ingen sådan studie finns månntro?
Vilken av studierna på sidan var det som du inte klarade av att läsa?
1. Afsar et al., SSRN., Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting,
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3734478.
2.
Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,
https://www.sciencedirect.com/science/article/pii/S1201971220325066.
3.
Alam et al., European Journal ofMedical and Health Sciences, doi:10.24018/ejmed.2020.2.6.599, Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study,
https://ejmed.org/index.php/ejmed/article/view/599.
7.
Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1, Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study,
https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.
8.
Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231, Ivermectin benefit: from scabies to COVID-19, an example of serendipity,
https://www.sciencedirect.com/science/article/pii/S015196382030627X.
9.
Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223, Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience,
https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1.
10.
Cadegiani et al., medRxiv, doi:10.1101/2020.10.31.20223883, Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients,
https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1.
11.
Camprubí et al., PLoS ONE, 15:11, doi:10.1371/journal.pone.0242184, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients,
https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0242184.
12.
Carvallo et al., medRxiv, doi:10.1101/2020.09.10.20191619, Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19,
https://www.medrxiv.org/content/10.1101/2020.09.10.20191619v1.
13.
Carvallo (B) et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007, Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel,
https://medicalpressopenaccess.com/upload/1605709669_1007.pdf.
14.
Carvallo (C) et al., NCT04425850, Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR),
https://clinicaltrials.gov/ct2/show/results/NCT04425850.
15.
Chaccour et al., Research Square, doi:10.21203/rs.3.rs-116547/v1, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial,
https://www.researchsquare.com/article/rs-116547/v1.
16.
Chachar et al., International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378, Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,
https://www.ijsciences.com/pub/article/2378.
17.
Concato et al., NEJM, 342:1887-1892, doi:10.1056/NEJM200006223422507,
https://www.nejm.org/doi/full/10.1056/nejm200006223422507.
20.
Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v2, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic,
https://www.researchsquare.com/article/rs-100956/v3.
21.
Elgazzar (B) et al., Research Square, doi:10.21203/rs.3.rs-100956/v2, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic,
https://www.researchsquare.com/article/rs-100956/v3.
22.
Espitia-Hernandez et al., Biomedical Research, 31:5, Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study,
https://www.biomedres.info/biomedi..-proof-of-concept-study-14435.html.
23.
Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979, Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial),
https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1.
24.
Hashim et al., medRxiv, doi:10.1101/2020.10.26.20219345, Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq,
https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1.
25.
Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248, A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin,
https://www.sciencedirect.com/science/article/pii/S0924857920304684.
26.
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007, Ivermectin treatment may improve the prognosis of patients with COVID-19,
https://www.archbronconeumol.org/e..ognosis-articulo-S030028962030288X.
27.
Krolewiecki et al., SSRN, Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial,
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649.
28.
Lee et al., Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482, Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines,
https://jamanetwork.com/journals/j..nternalmedicine/fullarticle/226373.
29.
Mahmud et al., Clinical Trial Results, NCT04523831, Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,
https://clinicaltrials.gov/ct2/show/results/NCT04523831?view=results.
30.
McLean et al., Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100, Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525010/.
31.
Niaee et al., Research Square, doi:10.21203/rs.3.rs-109670/v1, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial,
https://www.researchsquare.com/article/rs-109670/v1.
33.
Podder et al., IMC J. Med. Science, 14:2, July 2020, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study,
http://imcjms.com/registration/journal_abstract/353.
34.
Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009, Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study),
https://www.sciencedirect.com/science/article/pii/S0012369220348984.
35.
Shouman et al., NCT04422561, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19,
https://clinicaltrials.gov/Provide..cs/61/NCT04422561/Prot_SAP_000.pdf.
36.
Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066, Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru,
https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1.
37.
Spoorthi et al., IAIM, 2020, 7:10, 177-182, Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2,
http://iaimjournal.com/wp-content/..oads/2020/10/iaim_2020_0710_23.pdf.
38.
Sweeting et al., Statistics in Medicine, doi:10.1002/sim.1761, What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data,
https://onlinelibrary.wiley.com/doi/10.1002/sim.1761.
39.
Treanor et al., JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016, Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial,
https://jamanetwork.com/journals/jama/fullarticle/192425.
40.
Vallejos et al., Coronavirus in Argentina: Warnings and evidence on the consumption of ivermectin against Covid-19,
https://totalnewsagency.com/2020/1..de-ivermectina-contra-el-covid-19/.
41.
Zhang et al., JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690, What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes,
https://jamanetwork.com/journals/jama/fullarticle/188182.